Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)

Idiopathic Pulmonary Fibrosis Clinical Trial

Official title:

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial for the Safety and Efficacy of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01504334
• Other study ID #: KAWIN-001
• Status: Recruiting
• Phase: Phase 2
• First received: December 30, 2011
• Last updated: February 5, 2012
• Start date: January 2012
• Est. completion date: March 2013

Study information

• Verified date: February 2012
• Source: Beijing Kawin Technology Share-Holding Co., Ltd.
• Contact: Xu Zuojun, MD
• Phone: +86-10-65295039
• Email: xuzj[@]hotmail.com
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of lung disease characterized by fibrosis of the supporting framework (interstitium) of the lungs. By definition, the term is used only when the cause of the pulmonary fibrosis is unknown ("idiopathic"). Microscopically, lung tissue from patients shows a characteristic set of histologic/pathologic features known as usual interstitial pneumonia (UIP). UIP is therefore the pathologic counterpart of IPF.Idiopathic pulmonary fibrosis is characterized by radiographically evident interstitial infiltrates predominantly affecting the lung bases and by progressive dyspnea and worsening of pulmonary function. No therapy has been clearly shown to prolong survival. The current strict definition of idiopathic pulmonary fibrosis provides a new focus for basic and clinical research that will improve insight into the pathogenesis of this disorder and stimulate the development of novel therapies.

Pirfenidone has proven antifibrotic and anti-inflammatory properties in various in vitro systems and animal models of pulmonary fibrosis, although its precise mechanism of action remains unclear. It attenuates fibroblast proliferation, production of fibrosis-associated proteins and cytokines, and the increased biosynthesis and accumulation of extracellular matrix in response to cytokines such as transforming growth factor-β. It is also shown to slow tumor cell proliferation by inhibiting fibroblast growth factor, epidermal growth factor and platelet-derived growth factor.

Pirfenidone has not been widely approved for clinical use in China, in this study, safety and efficacy were evaluated to see if pirfenidone has a significant advantage over placebo in terms of improving lung function and life quality etc. (see primary and secondary criteria) or slows down the deterioration of lung function in Chinese subjects diagnosed with IPF.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: March 2013
• Est. primary completion date: November 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Written informed consent signed;

2. 18-75 years of age;

3. Clinically or multidisciplinarily diagnosed idiopathic pulmonary fibrosis(see 2011 guidance );

4. Resting state PaO2=50mg, FVC%=45% normal predicted value and DLCO=30% normal predicted value.

Exclusion Criteria:

1. Allergic to pirfenidone;

2. Dyspnea symptoms relieved in the past 6 months;

3. Patients in acute exacerbation phase;

4. Diabetic patients whose fasting venous glucose >11.1 mmol/L;

5. Patients with malignant tumor and hemorrhagic diseases;

6. Patients with serious underlying pulmonary disease;

7. Patients with serious heart disease(NYHA class ?-?), liver disease(ALT or AST 2 times above the upper level of normal value range), kidney disease(Cr above the upper level of normal value range);

8. Patients who has taken Acetylcysteine in the past 3 months;

9. Patients who has taken Prednisone>15mg/day(or other equivalent amount of glucocorticoid) and/or Immunosuppresants in the past 3 months;

10. Patients who has taken interferon, penicillamine, colchine or other agents for the treatment of IPF;

11. Pregnant or lactating women;

12. Participated in other clinical trials in the past 1 month;

13. The investigator assessed as inappropriate to participate in this clinical trial.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Fibrosis
• Idiopathic Interstitial Pneumonias
• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Intervention

Drug:
• Pirfenidone
Pirfenidone(200mg)tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets(600mg)will be taken once a day, 1 tablet each time from the first to the 48th week.
• Placebo
Placebo(without active ingredient) tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets(600mg)will be taken once a day, 1 tablet each time from the first to the 48th week for both groups.

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing	Beijng

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Kawin Technology Share-Holding Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in forced vital capacity (FVC)	Changes in FVC from 48 weeks to baseline	48 weeks	No
Secondary	Changes in lung function (including arterial blood gas analysis)	Lung function will be assessed as improved/stabilized/exacerbated from 48 weeks to baseline.	48 weeks	No
Secondary	Acute Exacerbation during the whole treatment procedure(frequency and severity)	The following clinical deterioration symptoms within a month that cannot be explained by other reasons will be assessed as acute exacerbation: Aggravated dyspnea; Newly discovered chest interstitial lung abnormality by radiograph/HRCT, without pneumothorax or pleural effusion; PaO2 decreases =10mm Hg,heart failure or pulmonary embolism excluded.; Acute Exacerbation can be assessed if 1 and 2 appear or 1 and 3 appear.	48 weeks	No
Secondary	Progression-free time	Progression of disease during the whole study period is defined as follows: Progressive dyspnea (objective evaluation); FVC absolute value progressively and constantly decreases compared with baseline value; DLCO absolute value (after hemoglobin calibration) progressively and constantly decreases compared with baseline value; Fibrosis progressive deterioration by HRCT examination; Acute Exacerbation; Death caused by respiratory failure.	48 weeks	No
Secondary	6 Minute Walk Test (6MWT ): Changes in 6 minute walk distance (6MWD) and SpO2 from 48 weeks to baseline	Method: The walking test is conducted in a corridor 33 meters long. The patient is instructed to "walk from end to end, covering as much ground as they can in the allotted time". The total distance ambulated in meters during the 6-minute walk test and the number of rest stops is recorded. 6MWD, weight, heart rate, BP, SpO2, and a self-reported rating of perceived exertion [modified Borg RPE scale rating (0 to 10 scale)] is recorded after the walk.	48 weeks	No
Secondary	Borg RPE scale rating improvement rate during the whole study period	Patient percentage whose Borg RPE scale rating improves more than 1 level.	48 weeks	No
Secondary	Lung interstitial change observed by HRCT	Changes in HRCT lung interstitial evaluation score from 48 weeks to baseline	48 weeks	No
Secondary	Life quality: assessed by St. George respiratory questionnaire (SGRQ).	Life quality will be assessed as improved if SGRQ single or total score increased >4% when completing the trial; Life quality will be assessed as stabilized if SGRQ single or total score changes within the range of 4% when completing the trial; Life quality will be assessed as exacerbated if SGRQ single or total score decreased >4% when completing the trial.	48 weeks	No